ADMA Biologics (NASDAQ:ADMA) Downgraded to “Sell” at StockNews.com

ADMA Biologics (NASDAQ:ADMA) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Monday.

Other research analysts have also recently issued research reports about the company. HC Wainwright raised their target price on ADMA Biologics from $4.50 to $5.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Mizuho boosted their target price on shares of ADMA Biologics from $6.00 to $7.00 in a report on Thursday, August 10th. Finally, Raymond James increased their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.00.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.09 during midday trading on Monday, reaching $3.64. 1,892,125 shares of the company were exchanged, compared to its average volume of 2,311,568. The company’s 50 day moving average price is $3.93 and its two-hundred day moving average price is $3.71. The company has a market cap of $818.67 million, a P/E ratio of -18.20 and a beta of 0.81. ADMA Biologics has a 12 month low of $2.24 and a 12 month high of $4.65. The company has a debt-to-equity ratio of 1.03, a quick ratio of 2.49 and a current ratio of 6.35.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The firm had revenue of $60.12 million for the quarter, compared to analysts’ expectations of $55.45 million. ADMA Biologics had a negative return on equity of 27.55% and a negative net margin of 19.36%. During the same quarter in the previous year, the company earned ($0.07) earnings per share. On average, sell-side analysts expect that ADMA Biologics will post -0.06 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Brian Lenz sold 211,578 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $4.60, for a total transaction of $973,258.80. Following the sale, the chief financial officer now owns 782,013 shares in the company, valued at $3,597,259.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Brian Lenz sold 211,578 shares of ADMA Biologics stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $4.60, for a total transaction of $973,258.80. Following the transaction, the chief financial officer now owns 782,013 shares in the company, valued at $3,597,259.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Young Kwon purchased 25,000 shares of the stock in a transaction dated Thursday, August 24th. The shares were acquired at an average price of $3.90 per share, for a total transaction of $97,500.00. Following the acquisition, the director now directly owns 277,401 shares of the company’s stock, valued at approximately $1,081,863.90. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 2,405,351 shares of company stock valued at $9,875,175. 6.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp grew its stake in ADMA Biologics by 217.9% in the third quarter. State Street Corp now owns 9,423,422 shares of the biotechnology company’s stock valued at $22,899,000 after purchasing an additional 6,459,197 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in ADMA Biologics by 181.7% in the first quarter. Assenagon Asset Management S.A. now owns 6,665,021 shares of the biotechnology company’s stock valued at $22,061,000 after purchasing an additional 4,299,301 shares in the last quarter. Millennium Management LLC grew its stake in ADMA Biologics by 206.7% in the fourth quarter. Millennium Management LLC now owns 5,296,781 shares of the biotechnology company’s stock valued at $20,552,000 after purchasing an additional 3,569,778 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in shares of ADMA Biologics during the 2nd quarter worth about $12,658,000. Finally, Caligan Partners LP bought a new stake in shares of ADMA Biologics during the 4th quarter worth about $10,383,000. Hedge funds and other institutional investors own 73.58% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.